Presenter: T.F. DeLaney Presenter's Affiliation: Massachusetts General Hospital, Boston, MA Type of Session: Scientific
Background The management of extremity soft tissue sarcomas has evolved from amputation to limb sparing surgery with radiation therapy. While local control rates are generally quite high, the development of distant metastases remains a significant problem. This current study was undertaken to determine if the addition of chemotherapy reduces the incidence of metastases and increases overall survival
48 patients with large (>8cm) high grade extremity soft tissue sarcomas were enrolled.
Patients received 3 cycles of pre-operative chemotherapy consisting of Mesna, Adriamycin, Ifosfamide, and Dacarbazine (MAID)interdigitated with radiotherapy (44 Gy).
Following completion of this therapy patients had a three week break, followed by resection.
If surgical margins were positive an additional 16 Gy was administered
All patients were scheduled to receive 3 more cycles of MAID post-operatively.
Median age was 50 years
Median tumor size was 14 cm.
Median follow-up was 4 years.
83% of patients got all 6 cycles of MAID.
Freedom from distant metastases was 75%, which was significantly higher than 44% for matched historical controls.
Disease free survival(DFS) was 70% versus 42% for the historical controls.
2 year DFS was 90% for the experimental group.
Overall survival was also significantly higher, 87% versus 58%.
25% of patients had at least one episode of febrile neutropenia.
30% had moist skin desquamation, and 30% had delayed wound healing.
Author's Conclusions Treatment with neoadjuvant MAID chemotherapy interdigitated with preoperative radiotherapy, surgery, and postoperative MAID chemotherapy +/- postoperative boost radiotherapy appears to be effective in reducing distant metastases and increasing disease free survival and overall survival in this population, as compared to historic controls who mostly had surgery and radiation therapy.
The results of this study are consistant with findings from a recent RTOG study.
This suggests that pre-operative chemotherapy should be considered in patients with large, high grade extremity soft tissue sarcomas.
However, comparisons to historical controls can be fraught with problems because of multiple confounding variables and differences in follow-up time between the groups.
Additional prospective studies are needed to evaluate this approach
Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology and Pharmacia Oncology.
Sep 22, 2011 - Tumor necrosis factor-α and melphalan-based isolated limb perfusion therapy has a limb salvage rate of 81 percent in patients with locally advanced extremity soft tissue sarcomas who would have otherwise undergone amputation, according to a study published online Sept. 19 in the Journal of Clinical Oncology.